Literature DB >> 16823870

Bioactive glass S53P4 in frontal sinus obliteration: a long-term clinical experience.

Matti Peltola1, Kalle Aitasalo, Jouko Suonpää, Matti Varpula, Antti Yli-Urpo.   

Abstract

BACKGROUND: Synthetic, osteoconductive, and antimicrobial bioactive glass (BAG) has been used in many surgical applications.
METHODS: BAG was used as obliteration material in a series of osteoplastic frontal sinus operations on 42 patients suffering from chronic frontal sinusitis, which could not be cured with other means of treatment.
RESULTS: Accurate obliteration of sinuses was achieved in 39 patients. Uneventful recovery and clinical outcome were seen in 92% of the patients. Histopathologic samples harvested at 1, 5, and 10 years after obliteration revealed a healing process progressing from the fibrous tissue phase to bone formation with scattered fibrous tissue and bony obliteration maintaining BAG granule remnants. Fourier-transform infrared (FTIR) studies showed bone produced by BAG to be similar to natural frontal bone. Micorobiologic cultures obtained with histologic samples revealed no growth of bacteria.
CONCLUSIONS: BAG appears to be a reliable frontal sinus obliteration material, providing favorable conditions for total bony sinus obliteration. (c) 2006 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16823870     DOI: 10.1002/hed.20436

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  20 in total

Review 1.  [Obliteration of mastoid cavities: 30 years of experience with recommendations for surgical strategy].

Authors:  G Schimanski; E Schimanski
Journal:  HNO       Date:  2015-08       Impact factor: 1.284

Review 2.  Bioactive-glass in Oral and Maxillofacial Surgery.

Authors:  Andrea Corrado Profeta; Christoph Huppa
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2015-05-21

3.  Bioactive glass granules for mastoid and epitympanic surgical obliteration: CT and MRI appearance.

Authors:  Daniele Bernardeschi; Bruno Law-Ye; Franck Bielle; Baptiste Hochet; Olivier Sterkers; Didier Dormont; Nadya Pyatigorskaya
Journal:  Eur Radiol       Date:  2019-03-19       Impact factor: 5.315

4.  Frontal sinus obliteration with autologous calvarial bone graft: indications and results.

Authors:  Pierre Vironneau; André Coste; Virginie Prulière-Escabasse
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-08       Impact factor: 2.503

Review 5.  Mastoid Obliteration with Synthetic Materials: A Review of the Literature.

Authors:  Charalampos Skoulakis; Petros Koltsidopoulos; Arunachalam Iyer; Georgios Kontorinis
Journal:  J Int Adv Otol       Date:  2019-12       Impact factor: 1.017

Review 6.  Frontal Sinus Fractures: Evolving Clinical Considerations and Surgical Approaches.

Authors:  Mark A Arnold; Sherard A Tatum
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2019-02-04

7.  Effect of S53P4 bone substitute on staphylococcal adhesion and biofilm formation on other implant materials in normal and hypoxic conditions.

Authors:  R Pérez-Tanoira; M García-Pedrazuela; T Hyyrynen; A Soininen; A Aarnisalo; Mikko T Nieminen; V-M Tiainen; Y T Konttinen; T J Kinnari
Journal:  J Mater Sci Mater Med       Date:  2015-09-24       Impact factor: 3.896

8.  Effects of S53P4 bioactive glass on osteoblastic cell and biomaterial surface interaction.

Authors:  R Pérez-Tanoira; T J Kinnari; T Hyyrynen; A Soininen; L Pietola; V-M Tiainen; Y T Konttinen; A A Aarnisalo
Journal:  J Mater Sci Mater Med       Date:  2015-09-28       Impact factor: 3.896

9.  Osteoblast response to polymethyl methacrylate bioactive glass composite.

Authors:  M Hautamäki; V V Meretoja; R H Mattila; A J Aho; P K Vallittu
Journal:  J Mater Sci Mater Med       Date:  2010-02-17       Impact factor: 3.896

10.  Novel composite implant in craniofacial bone reconstruction.

Authors:  Matti J Peltola; Pekka K Vallittu; Ville Vuorinen; Allan A J Aho; Antti Puntala; Kalle M J Aitasalo
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-01       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.